Table 1.
Patient, Disease, and Transplant Characteristics
| All Groups |
D1-3 |
D4-5 |
P-value (for D score) |
TMTV0 |
TMTVlow |
TMTVhigh |
P-value (for TMTV) | |
|---|---|---|---|---|---|---|---|---|
| N | 96 | 73 | 23 | 61 | 17 | 17 | ||
| Median Age (range) | 33 (18-71) | 34 (18-66) | 30 (18-71) | 0.64 | 33.1(18-66) | 36 (20-71) | 29 (18-67) | 0.89 |
| Gender | 0.55 | 0.76 | ||||||
| Male | 49 (51%) | 36 (49%) | 13(56%) | 30 (48%) | 10 (58.8%) | 8 (47.1%) | ||
| Female | 47 (49%) | 37 (51%) | 10 (44%) | 31 (52%) | 7 (41.2%) | 9 (52.9%) | ||
| KPS | 0.08 | 0.10 | ||||||
| <80% | 1 (1.0%) | 0 | 1 (4.3%) | 0 | 0 | 1 (5.9%) | ||
| ≥80% | 93 (96.9%) | 71 (97.3%) | 22 (95.7%) | 60 (95%) | 17 (100.0%) | 16 (94.1%) | ||
| Duration of 1st remission | 0.12 | 0.43 | ||||||
| ≥1 year | 29 (30%) | 25 (34%) | 4 (17%) | 20 (30%) | 3 (17.6%) | 5 (29.4%) | ||
| <1 year | 67 (70%) | 48 (66%) | 19 (83%) | 41(70%) | 14 (82.4%) | 12 (70.6%) | ||
| Prior XRT | 0.04 | 0.04 | ||||||
| No | 62 (65%) | 43 (59%) | 19 (83%) | 35 (57%) | 15 (88.2%) | 12 (70.6%) | ||
| Yes | 34 (35%) | 30 (41%) | 4 (17%) | 26 (43%) | 2 (11.8%) | 5 (29.4%) | ||
| Ann Arbor Stage | 0.67 | 0.15 | ||||||
| I/II | 37 (38%) | 29 (40%) | 8 (35%) | 26 (40%) | 3 (17.6%) | 7 (41.2%) | ||
| III/IV | 59 (62%) | 44 (60%) | 15 (65%) | 35 (60%) | 14 (82.4%) | 10 (58.8%) | ||
| B symptoms | 0.83 | 0.57 | ||||||
| No | 44 (46%) | 33 (45%) | 11 (48%) | 28 (44%) | 9 (52.9%) | 6 (35.3%) | ||
| Yes | 52 (54%) | 40 (55%) | 12 (52%) | 33 (56%) | 8 (47.1%) | 11 (64.7%) | ||
| Extranodal ds | 0.42 | <0.01 | ||||||
| No | 65 (68%) | 51 (70%) | 14 (61%) | 47 (75%) | 5 (29.4%) | 12 (70.6%) | ||
| Yes | 31 (32%) | 22 (30%) | 9 (39%) | 14 (25%) | 12 (70.6%) | 5 (29.4%) | ||
| BM involvement | 0.63 | 0.21 | ||||||
| No | 85 (88%) | 64 (88%) | 21 (91%) | 55 (90%) | 13 (76.5%) | 16 (94.1%) | ||
| Yes | 11 (12%) | 9 (12%) | 2 (9%) | 6 (10%) | 4 (23.5%) | 1 (5.9%) | ||
| Histology | 0.28 | 0.28 | ||||||
| Nodular Sclerosis | 83 (86%) | 62 (85%) | 21 (91%) | 52 (84%) | 16 (94.1%) | 15 (88.2%) | ||
| Mixed Cellularity | 6 (6%) | 4 (5%) | 2 (9%) | 3(4%) | 1 (5.9%) | 2 (11.8%) | ||
| Other | 7 (8%) | 7 (10%) | 0 | 6 (12%) | 0 | 0 | ||
| LDH | 0.82 | 0.77 | ||||||
| <ULN | 85 (88.5%) | 64 (87.7%) | 21 (91.3%) | 54(87%) | 15 (88.2%) | 16 (94.1%) | ||
| ≥ULN | 7 (7.3%) | 5 (6.8%) | 2 (8.7%) | 4(6%) | 2 (11.8%) | 1 (5.9%) | ||
| Albumin | 0.63 | |||||||
| <3.5 g/dL | 86 (89.6%) | 65 (89.0%) | 21 (91.3%) | 55(89%) | 16 (94.1%) | 15 (88.2%) | 0.62 | |
| ≥3.5 g/dL | 6 (6.3%) | 4 (5.5%) | 2 (8.7%) | 3(5%) | 1 (5.9%) | 2 (11.8%) | ||
| ALC | 0.03 | 0.30 | ||||||
| Missing | 4 (4.2%) | 4 (5.5%) | 0 | 3 | ||||
| <1×103/mL | 42 (43.8%) | 27 (37.0%) | 15 (65.2%) | 45(73%) | 9 (52.9%) | 10 (58.8%) | ||
| ≥1×103/mL | 50 (52.1%) | 42 (57.5%) | 8 (34.8%) | 13(21%) | 8 (47.1%) | 7 (41.2%) | ||
| Stem cell source | 0.46 | 0.78 | ||||||
| Marrow | 1 (1.0%) | 1 (1.4%) | 0 | 16 (94.1%) | 16 (94.1%) | |||
| PBSC | 85 (88.5%) | 63 (86.3%) | 22 (95.7%) | 4(6%) | 1 (5.9%) | 1 (5.9%) | ||
| Marrow+PBSC | 10 (10.4%) | 9 (12.3%) | 1 (4.3%) | 22 (35%) | 0 | 0 | ||
| 35(59%) | ||||||||
|
Median CD34 cell dose in 106/kg
(range) |
5.0 (0.3-24.3) | 4.9 (0.3-24.3) | 5.6 (1.3-19.0) | 0.27 | 4.5(0.3-24.3) | 5.2 (1.8-19.0) | 5.8 (1.3-17.8) | 0.23 |
| Plerixafor | 0.07 | 0.09 | ||||||
| Missing | 3 (3.1%) | 2 (2.7%) | 1 (4.3%) | 1 | 1 (5.9%) | 1 (5.9%) | ||
| No | 79 (82.3%) | 63 (86.3%) | 16 (69.6%) | 53(85.5%) | 13 (76.5%) | 11 (64.7%) | ||
| Yes | 14 (14.6%) | 8 (11.0%) | 6 (26.1%) | 8(13%) | 3 (17.6%) | 5 (29.4%) | ||
| >2 chemo regimen | 0.03 | 0.04 | ||||||
| NO | 25 (26.0%) | 15 (20.5%) | 10 (43.5%) | 11 (20%) | 7 (41.2%) | 7 (41.2%) | ||
| YES | 71 (74.0%) | 58 (79.5%) | 13 (56.5%) | 50 (80) | 10 (58.8%) | 10 (58.8%) | ||
| Deauville score pre-AHCT | <0.01 | <0.01 | ||||||
| 1 | 57 (59.4%) | 57 (78.1%) | 0 | 57(92%) | 0 | 0 | ||
| 2 | 4 (4.2%) | 4 (5.5%) | 0 | 4(7%) | 0 | 0 | ||
| 3 | 12 (12.5%) | 12 (16.4%) | 0 | 0 | 8 (47.1%) | 3 (17.6%) | ||
| 4 | 19 (19.8%) | 0 | 19 (82.6%) | 0 | 9 (52.9%) | 10 (58.8%) | ||
| 5 | 4 (4.2%) | 0 | 4 (17.4%) | 0 | 0 | 4 (23.5%) | ||
| Consolidation XRT | 0.58 | 0.45 | ||||||
| Yes | 33 (34%) | 24 (32.9%) | 9 (39.1%) | 19 (34%) | 8 (47%) | 6 (35%) | ||
| No | 63 (66%) | 49 (67.1%) | 14 (60.9%) | 42 (66%) | 9 (53%) | 11 (65%) |
Abbreviations: AHCT, autologous hematopoietic cell transplant; ALC, absolute lymphocyte count; BM, bone marrow; CR1, first complete remission; ds, disease; D, Deauville score category; KPS, Karnofsky performance status; TMTV; total metabolic tumor volume; ULN, upper laboratory limit; XRT, radiotherapy. PBSC peripheral blood stem cells